To further establish the efficacy of MRK-740, five glioblastoma stem cell lines, each with distinct combinations of genetic mutations31 were co-treated with CMPD1 and either MRK-740 or matched inactive compound MRK-740-NC which does not inhibit PRDM930, followed by drug holiday (Fig. 3g). The gene discussed is SOX9; the disease is glioblastoma.